Can a spray alter skin bacteria to help lymphoma lesions?

NCT ID NCT05728879

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a wound spray (APR-TD011) on skin lesions caused by cutaneous T cell lymphoma. Researchers want to see if the spray can reduce harmful bacteria (Staphylococcus aureus) on the skin and if it is well tolerated. The study will include 30 adults with early-stage mycosis fungoides. It is a pilot study, meaning it is a small first step to gather information, not a treatment for the lymphoma itself.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS T CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mycosis fungoides primary cutaneous T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dermatology CTU

    Chicago, Illinois, 60611, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••